SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-217954
Filing Date
2022-08-11
Accepted
2022-08-11 07:05:58
Documents
13
Period of Report
2022-08-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d346123d8k.htm   iXBRL 8-K 32543
2 EX-10.1 d346123dex101.htm EX-10.1 50165
  Complete submission text file 0001193125-22-217954.txt   222841

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fulc-20220811.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20220811_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20220811_pre.xml EX-101.PRE 11264
7 EXTRACTED XBRL INSTANCE DOCUMENT d346123d8k_htm.xml XML 3350
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 221153637
SIC: 2834 Pharmaceutical Preparations